Home / Resources / Test Your Knowledge / Question #878

Question #878

Mar 25, 2017

The diabetes drug empagliflozin reduces all of the following CV risk factors except:


Answer: c. Low-density lipoprotein cholesterol

Explanation:  Empagliflozin is the only diabetes medication that is approved by the US Food and Drug Administration for both glycemic control and cardiovascular death risk reduction in adult patients with type 2 diabetes and cardiovascular disease. However, dose-related increases in low-density lipoprotein cholesterol have been observed in patients taking the drug. In clinical trials, low-density lipoprotein cholesterol increased by 2.3%, 4.6%, and 6.5% in patients treated with placebo, empagliflozin 10 mg, and empagliflozin 25 mg, respectively.

JARDIANCE® (empagliflozin) Prescribing Information. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf. Accessed February 6, 2017.

Briand F, et al. Diabetes. 2016;65(7):2032-2038.   Briand F, et al. Diabetes. 2016;65(7):2032-2038.

Monthly Essentials: Empagliflozin and CV Death in Type 2 Diabetes